

Mirvetuximab soravtansine (solution)

Cat. No.:	HY-132258A	
CAS No.:	1453084-37-1	
Molecular Weight:	150000	
Target:	Antibody-Drug Conjugates (ADCs)	Mirvetuximab soravtansine (solution)
Pathway:	Antibody-drug Conjugate/ADC Related	
Storage:	-80°C, protect from light	

BIOLOGICAL ACTIVITY

Description	Mirvetuximab soravtansine (IMGN853) solution is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage ^[1] .
In Vitro	Mirvetuximab soravtansine (IMGN853; 8 nM; 6 h; IGROV-1 cells) combined with Carboplatin (HY-17393) promotes synergistic growth inhibitory effects and cell cycle perturbations in vitro ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Mirvetuximab soravtansine (IMGN853; 5 mg/kg; i.v.; female severe combined immunodeficient (SCID) mice with patient-derived xenografts) potentiates the antitumor activity of Carboplatin in vivo ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA